- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 1NKEMIA Aktie jetzt für 0€ handeln |
0 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| AMGEN | 299,25 | -0,18 % | Amgen: Phase 3 Trial Of TEPEZZA Meets Primary And Key Secondary Endpoints | THOUSAND OAKS (dpa-AFX) - Amgen (AMGN) announced positive topline results from a Phase 3 trial of TEPEZZA administered by subcutaneous injection via an on-body injector in participants with... ► Artikel lesen | |
| 4SC | 0,100 | -23,37 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 16.12.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 16.12.2025Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 16.12.2025ISIN NameDE000A3E5C40 4SC... ► Artikel lesen | |
| AAP IMPLANTATE | 1,420 | 0,00 % | AAP Implantate AG zeigt strukturelle Stärke | ||
| COSCIENS BIOPHARMA | 1,750 | -23,25 % | Cosciens Biopharma Inc: Cosciens Biopharma does not say why shares are spiking | ||
| ALDEYRA | 1,370 | +1,48 % | Aldeyra Therapeutics, Inc.: Aldeyra Therapeutics to Participate in the Jefferies Global Healthcare Conference in London | Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated diseases, today announced... ► Artikel lesen | |
| AGIOS | 28,600 | -0,69 % | Agios Pharmaceuticals, Inc.: Agios Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update | PYRUKYND (mitapivat) worldwide net revenues of $20.0 million in fourth quarter and $54.0 million for full yearAQVESME (mitapivat) for thalassemia now available in U.S. following FDA approvalCompany... ► Artikel lesen | |
| AGENUS | 3,640 | +0,55 % | Agenus Inc.: Agenus gibt die Aufnahme des ersten Patienten in die globale Phase-3-Studie BATTMAN bekannt, in der die Immuntherapie-Kombination aus BOT und BAL bei metastasiertem kolorektalem Karzinom der MSS- oder pMMR-Gruppe untersucht wird | Eine wegweisende Zulassungsstudie, deren Ziel darin besteht, die Behandlungsergebnisse bei MSS mCRC neu zu definieren, einer Form, die etwa 95 aller Fälle von metastasiertem Darmkrebs ausmacht... ► Artikel lesen | |
| ADAPTIMMUNE THERAPEUTICS | 0,013 | +62,50 % | Adaptimmune Therapeutics PLC: Adaptimmune Announces Changes to Board and Executive Leadership Team | Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - November 17, 2025) - Adaptimmune Therapeutics plc (OTC Pink: ADAPY) ("Adaptimmune" or the "Company") today announced changes... ► Artikel lesen | |
| ACTINIUM | 1,028 | +1,58 % | Actinium Pharmaceuticals, Inc.: Actinium Pharmaceuticals Announces New Pan-Tumor Preclinical Data for ATNM-400 in Solid Tumors and Differentiated Mechanism for Actimab-A in AML to be Presented at 2026 AACR Annual Meeting | New data underscoring the potential of ATNM-400 as a first-in-class Ac-225 radioconjugate with broad pan-tumor efficacy across multiple solid tumor models
Actimab-A... ► Artikel lesen | |
| AKEBIA | 1,241 | +1,60 % | H.C. Wainwright reiterates Akebia Therapeutics stock rating at buy | ||
| ALKERMES | 29,470 | -1,17 % | Alkermes plc: Alkermes Announces Initiation of Phase 3 Brilliance Studies Evaluating Alixorexton for the Treatment of Narcolepsy Type 1 and Type 2 | Alkermes plc (Nasdaq: ALKS) today announced the initiation of the Brilliance Studies, a phase 3 program evaluating the safety and efficacy of alixorexton compared to placebo in adults with narcolepsy... ► Artikel lesen | |
| ABEONA THERAPEUTICS | 4,114 | -1,34 % | Abeona Therapeutics Inc.: Abeona Therapeutics Announces New Qualified Treatment Center for ZEVASKYN in New York | CLEVELAND, April 02, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced activation of NewYork-Presbyterian/Columbia University Irving Medical Center in New York, NY as... ► Artikel lesen | |
| 3SBIO | 2,760 | +5,28 % | BOCI Raises 3SBio TP to HKD38.3, Rating Buy | ||
| ADVANCED PROTEOME THERAPEUTICS | - | - | Advanced Proteome Therapeutics Corp (2): Advanced Proteome to be delisted from NEX | ||
| ADOCIA | 4,582 | -0,52 % | Number of Shares and Voting Rights of ADOCIA as of February 28th, 2026 | Regulatory News:
Pursuant to the provisions of article L. 233-8 II of the French "Code de Commerce" and article 223-16 of the General Regulation of the French stock-market authorities (Autorité... ► Artikel lesen |
1NKEMIA IUCT GROUP SA gehört der Branche Biotechnologie an.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu 1NKEMIA IUCT GROUP SA finden Sie auf Wallstreet Online.